Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy (original) (raw)
References
Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M, Zambetti M: Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 16: 93–100, 1998 Google Scholar
Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz Jr AB, Hoehn JL, Lees AW, Dimitrov NV, Bear HD: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672–2685, 1998 Google Scholar
Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz Jr AB, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15: 2483–2493, 1997 Google Scholar
Filipits M, Suchomel RW, Dekan G, Haider K, Valdimarsson G, Depisch D, Pirker R: MRP and MDR1 gene expression in primary breast carcinomas. Clin Cancer Res 2: 1231–1237, 1996 Google Scholar
Nooter K, Brutel de la Riviere G, Klijn J, Stoter G, Foekens J: Multidrug resistance protein in recurrent breast cancer. Lancet 349: 1885–1886, 1997 Google Scholar
Nooter K, Brutel de la Riviere G, Look MP, van Wingerden KE, Henzen-Logmans SC, Scheper RJ, Flens MJ, Klijn JGM, Stoter G, Foekens JA: The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br J Cancer 76: 486–493, 1997 Google Scholar
Dexter DW, Reddy RK, Geles KG, Bansal S, Myint MA, Rogatko A, Leighton JC, Goldstein LJ: Quantitative reverse transcriptase-polymerase chain reaction measured expression of MDR1 and MRP in primary breast carcinoma. Clin Cancer Res 4: 1533–1542, 1998 Google Scholar
Ito K, Fujimori M, Nakata S, Hama Y, Shingu K, Kobayashi S, Tsuchiya S, Kohno K, Kuwano M, Amano J: Clinical signifi-cance of the increased multidrug resistance-associated protein (MRP) gene expression in patients with primary breast cancer. Oncol Res 10: 99–109, 1998 Google Scholar
Filipits M, Malayeri R, Suchomel RW, Pohl G, Stranzl T, Dekan G, Kaider A, Stiglbauer W, Depisch D, Pirker R: Expression of the multidrug resistance protein (MRP1) in breast cancer. Anticancer Res 19: 5043–5050, 1999 Google Scholar
Pohl G, Filipits M, Suchomel RW, Stranzl T, Depisch D, Pirker R: Expression of the lung resistance protein (LRP) in primary breast cancer. Anticancer Res 19: 5051–5056, 1999 Google Scholar
Wallner J, Depisch D, Hopfner M, Haider K, Spona J, Ludwig H, Pirker R: MDR1 gene expression and prognostic factors in primary breast carcinomas. Eur J Cancer 27: 1352–1355, 1991 Google Scholar
Filipits M, Suchomel RW, Zöchbauer S, Malayeri R, Pirker R: Clinical relevance of drug resistance genes in malignant diseases. Leukemia 10: 10–17, 1996 Google Scholar
Trock BJ, Leonessa F, Clarke R: Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 89: 917–931, 1997 Google Scholar
Chevillard S, Pouillart P, Beldjord C, Asselain B, Beuzeboc P, Magdelénat H, Vielh P: Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer 77: 292–300, 1996 Google Scholar
Chung HC, Rha SY, Kim JH, Roh JK, Min JS, Lee KS, Kim BS, Lee KB: P-glycoprotein: the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer. Breast Cancer Res Treat 42: 65–72, 1997 Google Scholar
Ro J, Sahin A, Ro JY, Fritsche H, Hortobagyi G, Blick M: Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum Path 21: 787–791, 1990 Google Scholar
Arnal M, Franco N, Fargeot P, Riedinger J-M, Brunet-Lecomte P, Lizard-Nacol S: Enhancement of mdr1 gene expression in normal tissue adjacent to advanced breast cancer. Breast Cancer Res Treat 61: 13–20, 2000 Google Scholar
Vargas-Roig LM, Gago FE, Tello O, Martin de Civetta MT, Ciocca DR: c-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer 84: 129–134, 1999 Google Scholar
Linn SC, Pinedo HM, van Ark-Otte J, van der Valk P, Hoekman K, Honkoop AH, Vermorken JB, Giaccone G: Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int J Cancer 71: 787–795, 1997 Google Scholar
Schneider J, Gonzalez-Roces S, Pollán M, Lucas R, Tejerina A, Martin M, Alba A: Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy. Breast Cancer Res 3: 183–191, 2001 Google Scholar
Yang X, Uziely B, Groshen S, Lukas J, Israel V, Russell C, Dunnington G, Formenti S, Muggia F, Press MF: MDR1 gene expression in primary and advanced breast cancer. Lab Invest 79: 271–280, 1999 Google Scholar
Faneyte IF, Kristel PM, and van de Vijver MJ: Determining MDR1/P-glycoprotein expression in breast cancer. Int J Cancer 93: 114–122, 2001 Google Scholar
Lizard-Nacol S, Genne P, Coudert B, Riedinger J-M, Arnal M, Sancy C, Brunet-Lecomte P, Fargeot P: MDR1 and thymidilate synthase (TS) gene expressions in advanced breast cancer: relationships to drug exposure, p53 mutations, and clinical outcome of the patients. Anticancer Res 19: 3575–3582, 1999 Google Scholar
Kickhoefer VA, Rajavel KS, Scheffer GL, Dalton WS, Scheper RJ, Rome LH: Vaults are up-regulated in multidrugresistant cancer cell lines. J Biol Chem 273: 8971–8974, 1998 Google Scholar